Armed with a batch of positive biomarker data, a rare disease player reaps $88M for the next big push in the clinic
Omega Funds and Abingworth teamed up to lead an $88 million round for Spruce, which is primarily focused on developing tildacerfont to treat classic congenital …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
